Saturday, January 16, 2021

Avacta enters license agreement with Canadian pharma company

Avacta Group has entered into a license agreement with Canada’s POINT Biopharma to provide access to the former’s pre|CISION technology for the development of tumour-activated radiopharmaceuticals.

The radiopharmaceutical market is expected to grow to $15 billion by 2025 and there is a substantial opportunity to grow much faster if safety and tolerability of these effective treatments can be improved.

POINT Biopharma is a clinical-stage pharmaceutical company focused on developing radioligands as precision medicines for the treatment of cancer.

Avacta’s proprietary pre|CISION chemistry can be used to modify a radioligand drug to form a tumour-activated prodrug.

The prodrug form is inactive in circulation until it enters the tumour micro-environment where it is activated by an enzyme called fibroblast activation protein (or FAP) that is present in high abundance in most solid tumours but not in healthy tissue.

Avacta’s pre|CISION technology therefore has the potential to improve the tolerability and achieve better clinical outcomes for patients compared with standard radiopharmaceuticals by targeting the radioligand treatment more specifically to cancer cells.

The agreement provides POINT with an exclusive license to the pre|CISION technology for use in the first radiopharmaceutical prodrug the company intends to develop, and a non-exclusive license to the pre|CISION platform for the development of a broader pipeline of FAP-activated radiopharmaceuticals.

As per the agreement, Avacta will receive an upfront fee and development milestones for the first radiopharmaceutical prodrug totaling $9.5 million.

Avacta will also receive milestone payments for subsequent radiopharmaceutical prodrugs of up to $8 million each, a royalty on sales of FAP-activated radiopharmaceuticals by POINT and a percentage of any sublicensing income received by POINT.

“I am very pleased to have established this partnership with POINT that allows Avacta to exploit its pre|CISION platform in a therapeutic area outside of our in-house focus on chemotherapy prodrugs,” said Alastair Smith, CEO of listed Wetherby-based Avacta Group.

“The clinical and commercial rationale for our pre|CISION prodrug platform is to improve the safety and efficacy of many existing drugs, as well as generating a pipeline of new and novel cancer therapies.

“In oncology, we believe that this approach will result in better response rates for monotherapies, and a greater safety margin, to enable their use with a larger patient population and as part of combination therapies.

“The in-house development of AVA6000 Pro-doxorubicin, the first of our pre|CISION chemotherapy prodrugs for which we have recently submitted a CTA filing in the UK to begin clinical trials in 2021, has already generated significant interest and this is highlighted by the agreement with POINT announced today.

“The potential of the pre|CISION platform to significantly improve outcomes for patients treated with existing cancer therapies through improved safety, tolerability and dosing regimens is enormous.

“In addition, Avacta is combining the pre|CISION technology with the Affimer platform to create an entirely new class of proprietary TMAC drug conjugates.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site and magazine but journalism costs money and we rely on advertising, print and digital revenues to help to support them.

With the Covid-19 pandemichaving a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites/magazines with either a small donation of even £1, or a subscription to our magazine, which costs just £31.50 per year, (inc p&P and mailed direct to your door) your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

As a subscriber, you will have unlimited access to our web site and magazine. You'll also be offered VIP invitations to our events, preferential rates to all our awards and get access to exclusive newsletters and content.

Just click here to subscribe and in the meantime may I wish you the very best.




Latest news

Leeds property firm makes four new appointments

Independent property firm, Adair Paxton, has appointed four new members of staff across its residential and commercial property divisions. Michelle Green, has been appointed as...

Supreme Court rules in favour of small business claims against commercial insurers

In good news for small firms, a Supreme Court ruling will see thousands have their disputed COVID-19 business interruption claims paid. It is expected that these...

Preventative healthcare specialist completes double acquisition of Lincs companies

Preventative healthcare specialist PAM Group has completed a double acquisition as it continues its buy-and-build strategy. The Warrington-based group has bought 66Fit and Physio Supplies...

2021 Business Predictions: Keith Hardman, Head of Cushman & Wakefield’s Leeds office

It’s that time of year, when Business Link invites the region’s business leaders to offer up their predictions for the year ahead. It has become...

Yorkshire manufacturers urged to have their say on life after Brexit

Small to medium-sized (SME) manufacturers in Yorkshire are being encouraged to have their say on trading beyond Brexit as part of the latest Manufacturing...

Bradford food manufacturer secures £90k grant

The Regal Food Group has secured £89,391 of grant support from the Leeds City Region Enterprise Partnership (the LEP) towards the expansion of its production facility and is creating 30 new jobs. Regal Foods is a well-established food manufacturer that has...

Related news

Supreme Court rules in favour of small business claims against commercial insurers

In good news for small firms, a Supreme Court ruling will see thousands have their disputed COVID-19 business interruption claims paid. It is expected that these...

Preventative healthcare specialist completes double acquisition of Lincs companies

Preventative healthcare specialist PAM Group has completed a double acquisition as it continues its buy-and-build strategy. The Warrington-based group has bought 66Fit and Physio Supplies...

2021 Business Predictions: Keith Hardman, Head of Cushman & Wakefield’s Leeds office

It’s that time of year, when Business Link invites the region’s business leaders to offer up their predictions for the year ahead. It has become...

Yorkshire manufacturers urged to have their say on life after Brexit

Small to medium-sized (SME) manufacturers in Yorkshire are being encouraged to have their say on trading beyond Brexit as part of the latest Manufacturing...

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close